10.21.21
Aptar Pharma, a global provider of Drug Delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a service provider for the development of pharmaceutical formulations, entered an exclusive partnership to co-develop and promote i2c’s pressurized metered dose inhaler (pMDI) technology, Respitab.
As part of the agreement, Aptar Pharma, a market leader in pulmonary drug delivery device solutions for COPD, will evaluate the commercial applications for Respitab, in particular for new, lower global warming potential (GWP) propellants.
Respitab is a propellant dispersible Tablet that eliminates the need for a complex mixing process used in standard pMDI manufacturing. A patented, innovative platform which enables the transition to the next generation of pMDIs for a range of active pharmaceutical ingredients (APIs) and combination products, Respitab is also a cost-effective approach for new chemical entity ( NCE ) and generic pMDI products, simplifying the manufacturing process for HFC 152a and other propellants.
Respitab is suitable for APIs with different physicochemical properties and has highly efficient Aerosol properties and dose uniformity characteristics. Respitab’s other advantages include reduced waste and API losses, as well as ease of scalability.
Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma said, “We are pleased to partner with i2c on this novel technology which brings many benefits to the
filling of metered dose inhalers. This development further enhances Aptar Pharma’s industry-leading portfolio of devices, which, combined with our broad spectrum of Aptar Pharma Services, allows us to offer end-to-end support to our clients and partners.”
“We are excited by this partnership with Aptar Pharma which brings together substantial synergies to provide a lower GWP product range to patients in the pMDI format, the most popular inhaler type across the globe,” added Glyn Taylor, CSO of i2c Pharmaceutical Services.
As part of the agreement, Aptar Pharma, a market leader in pulmonary drug delivery device solutions for COPD, will evaluate the commercial applications for Respitab, in particular for new, lower global warming potential (GWP) propellants.
Respitab is a propellant dispersible Tablet that eliminates the need for a complex mixing process used in standard pMDI manufacturing. A patented, innovative platform which enables the transition to the next generation of pMDIs for a range of active pharmaceutical ingredients (APIs) and combination products, Respitab is also a cost-effective approach for new chemical entity ( NCE ) and generic pMDI products, simplifying the manufacturing process for HFC 152a and other propellants.
Respitab is suitable for APIs with different physicochemical properties and has highly efficient Aerosol properties and dose uniformity characteristics. Respitab’s other advantages include reduced waste and API losses, as well as ease of scalability.
Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma said, “We are pleased to partner with i2c on this novel technology which brings many benefits to the
filling of metered dose inhalers. This development further enhances Aptar Pharma’s industry-leading portfolio of devices, which, combined with our broad spectrum of Aptar Pharma Services, allows us to offer end-to-end support to our clients and partners.”
“We are excited by this partnership with Aptar Pharma which brings together substantial synergies to provide a lower GWP product range to patients in the pMDI format, the most popular inhaler type across the globe,” added Glyn Taylor, CSO of i2c Pharmaceutical Services.
